Merck & Co., Inc. last reported quarterly results on Oct 29, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $18.1 billion (+4.7% year over year) and diluted EPS of $2.04. It usually reports 29–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 2, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 3, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 29, 2026
29 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
18,085
+4.7%
|
5,065
-12.4%
|
2.04
-12.1%
|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
16,607
+5.1%
|
-1,335
-130.2%
|
-0.54
-130.7%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
16,286
+4.9%
|
-4,240
-183.5%
|
-1.72
-185.6%
|
|
Feb 3, 2026
34 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
16,400
+5.0%
|
2,963
-20.8%
|
1.19
-19.3%
|
|
Oct 30, 2025
30 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
17,276
+3.7%
|
5,785
+83.2%
|
2.32
+87.1%
|
|
Jul 29, 2025
29 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
15,806
-1.9%
|
4,427
-18.8%
|
1.76
-17.8%
|
|
Apr 24, 2025
24 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
15,529
-1.6%
|
5,079
+6.7%
|
2.01
+7.5%
|
|
Feb 4, 2025
35 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
15,624
+6.8%
|
3,743
+405.3%
|
1.48
+406.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRK (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NJ
- Headquarters
- Rahway, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 310158
- Former names
- Merck & Co. Inc. (until Dec 9, 2014); SCHERING PLOUGH CORP (until Oct 29, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.